Rare head and neck cancers and pathological diagnosis challenges – A systematic review.
DOI:
https://doi.org/10.51168/sjhrafrica.v7i3.2467Keywords:
head and neck cancer, rare cancers, histopathological diagnosis, multidisciplinary care, quantitative diagnosis, Therapeutics, InnovationsAbstract
Background
Rare head and neck cancers present substantial diagnostic challenges due to overlapping histopathological features, complex molecular profiles, and clinical heterogeneity. Distinguishing metastatic disease, second primaries, and uncommon histological variants requires integration of qualitative pathological assessment and quantitative radiological evaluation. Advanced molecular tools, including next-generation sequencing and molecular classifier assays, are increasingly incorporated to improve diagnostic precision and therapeutic stratification.
Material and methods
A systematic review was conducted in accordance with PRISMA guidelines. Electronic databases including PubMed, MEDLINE, Scopus, Embase, Web of Science, and LILACS were searched for studies published between 2020 and 2024. Eligibility criteria included original research articles, case studies, and systematic investigations addressing rare head and neck cancers and associated diagnostic challenges. Studies unrelated to diagnostic methodology or not focused on rare entities were excluded. Extracted data items included author, year, country, study design, diagnostic modality, and clinical outcome relevance. Study quality was assessed using the STROBE checklist where applicable.
Results
Seven eligible studies were included. Findings demonstrated that qualitative histopathological diagnosis remains central to treatment planning but is limited by interobserver variability and tumor heterogeneity. Quantitative imaging modalities such as CT, MRI, and PET improved tumor localization and staging accuracy. Molecular profiling, biomarker identification, and gene expression assays enhanced primary site identification and prognostic assessment, particularly in cancers of unknown primary and salivary gland malignancies. Multidisciplinary tumor board discussions were consistently associated with optimized therapeutic decision-making and improved care coordination.
Conclusion
Accurate diagnosis of rare head and neck cancers requires integration of specialized pathological expertise, advanced molecular diagnostics, and structured multidisciplinary evaluation to guide individualized treatment strategies and improve clinical outcomes.
Future research
Collaborative international consortia will be necessary to generate adequately powered datasets for these uncommon tumors
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021 May;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338
Locati LD, Herman I, Benazzo M, Bonomo P, Ferri A, Maroldi R, Molteni G, Bossi P, Orlandi E. Implementing a virtual multidisciplinary clinical case discussion to manage rare and complex head and neck cancers: an expert-defined protocol proposal from the Italian Association of Head and Neck Oncology (AIOCC). Acta Otorhinolaryngologica Italica. 2023 Feb 28;43(1):82. https://doi.org/10.14639/0392-100X-N2368 PMid:36860154 PMCid:PMC9978303
Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L, RARECARE Working Group. Rare cancers of the head and neck area in Europe. European Journal of Cancer. 2012 Apr 1;48(6):783-96. https://doi.org/10.1016/j.ejca.2011.08.021 PMid:22051735
WHO Classification of Tumours Editorial Board. Head and Neck Tumours: WHO Classification of Tumours. (doi: not available)
Cheong SC, Vatanasapt P, Yi-Hsin Y, Zain RB, Kerr AR, Johnson NW. Oral cancer in South East Asia: Current status and future directions. Translational Research in Oral Oncology. 2017 Apr 18;2:2057178X17702921. https://doi.org/10.1177/2057178X17702921
dos Santos Menezes F, Fernandes GA, Antunes JL, Villa LL, Toporcov TN. Global incidence trends in head and neck cancer for HPV-related and-unrelated subsites: A systematic review of population-based studies. Oral oncology. 2021 Apr 1;115:105177. https://doi.org/10.1016/j.oraloncology.2020.105177 PMid:33561611
Conway DI, Purkayastha M, Chestnutt IG. The changing epidemiology of oral cancer: definitions, trends, and risk factors. British dental journal. 2018 Nov;225(9):867-73. https://doi.org/10.1038/sj.bdj.2018.922 PMid:30412558 PMCid:PMC11527597
Miranda-Filho A, Bray F. Global patterns and trends in cancers of the lip, tongue and mouth. Oral oncology. 2020 Mar 1;102:104551. https://doi.org/10.1016/j.oraloncology.2019.104551 PMid:31986342
Purkayastha M, McMahon AD, Gibson J, Conway DI. Trends of oral cavity, oropharyngeal and laryngeal cancer incidence in Scotland (1975-2012)-A socioeconomic perspective. Oral oncology. 2016 Oct 1;61:70-5. https://doi.org/10.1016/j.oraloncology.2016.08.015 PMid:27688107
Du E, Mazul AL, Farquhar D, Brennan P, Anantharaman D, Abedi‐Ardekani B, Weissler MC, Hayes DN, Olshan AF, Zevallos JP. Long‐term survival in head and neck cancer: impact of site, stage, smoking, and human papillomavirus status. The Laryngoscope. 2019 Nov;129(11):2506-13. https://doi.org/10.1002/lary.27807 PMid:30637762 PMCid:PMC6907689
Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, Matsuki T, Miura K, Kawakita D, Hirai H, Hoshino E. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Annals of Oncology. 2018 Apr 1;29(4):979-84. https://doi.org/10.1093/annonc/mdx771 PMid:29211833 PMCid:PMC5913639
Van Boxtel W, Locati LD, van Engen-Van Grunsven AC, Bergamini C, Jonker MA, Fiets E, Cavalieri S, Tooten S, Bos E, Quattrone P, Verhaegh GW. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. European journal of cancer. 2019 Mar 1;110:62-70. https://doi.org/10.1016/j.ejca.2018.12.035 PMid:30771738
Bergerot CD, Bergerot PG, Philip EJ, De Domenico EB, Manhaes MF, Pedras RN, Salgia MM, Dizman N, Ashing KT, Li M, Dale W. Assessment of distress and quality of life in rare cancers. Psycho‐Oncology. 2018 Dec;27(12):2740-6. https://doi.org/10.1002/pon.4873 PMid:30171792
Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh‐Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer. 2019 Sep 15;125(18):3184-97. https://doi.org/10.1002/cncr.32179 PMid:31150120
Prabhash K, Patil VM, Noronha V, Joshi AP, Bhattacharjee A, Mathrudev V, Bhelekar A, Nawale K, Agarwal JP, Ghosh-Laskar S, Budrukkar A. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer. Annals of Oncology. 2019 Oct 1;30:v455. https://doi.org/10.1093/annonc/mdz252.013
Lohia N, Bhatnagar S, Singh S, Prashar M, Subramananiam A, Viswanath S, Sahu PK, Rai A. Survival trends in oral cavity cancer patients treated with surgery and adjuvant radiotherapy in a tertiary center of Northern India: Where do we stand compared to the developed world?. SRM Journal of Research in Dental Sciences. 2019 Jan 1;10(1):26-31. https://doi.org/10.4103/srmjrds.srmjrds_58_18
Paterson IC, Eveson JW, Prime SS. Molecular changes in oral cancer may reflect aetiology and ethnic origin. European Journal of Cancer Part B: Oral Oncology. 1996 May 1;32(3):150-3. https://doi.org/10.1016/0964-1955(95)00065-8 PMid:8762870
Nibu KI, Hayashi R, Asakage T, Ojiri H, Kimata Y, Kodaira T, Nagao T, Nakashima T, Fujii T, Fujii H, Homma A. Japanese clinical practice guideline for head and neck cancer. Auris Nasus Larynx. 2017 Aug 1;44(4):375-80. https://doi.org/10.1016/j.anl.2017.02.004 PMid:28325607
Munoz J, Kurzrock R. Targeted therapy in rare cancers-adopting the orphans. Nature reviews Clinical oncology. 2012 Nov;9(11):631-42. https://doi.org/10.1038/nrclinonc.2012.160 PMid:22965154
Ramsay AD. Errors by locums. Histopathology departments already audit diagnostic errors. BMJ: British Medical Journal. 1996 Jul 13;313(7049):117. https://doi.org/10.1136/bmj.313.7049.117 PMid:8688744 PMCid:PMC2351479
Dixon A. Rare skin cancers in general practice. Australian family physician. 2007 Mar;36(3). PMID: 17339977
https://doi.org/10.1016/S0300-7073(06)73042-0
Kutikova L, Bowman L, Chang S, Long SR, Thornton DE, Crown WH. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. Journal of neuro-oncology. 2007 Jan;81(1):61-5. https://doi.org/10.1007/s11060-006-9197-y PMid:16773215
Belkacémi Y, Zouhair A, Ozsahin M, Azria D, Mirimanoff RO. Prognostic factors and management of rare cancers. Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique. 2006 Sep 6;10(6-7):323-9. https://doi.org/10.1016/j.canrad.2006.07.009 PMid:16952474
Jambhekar NA, Chaturvedi AC, Madur BP. Immunohistochemistry in surgical pathology practice: a current perspective of a simple, powerful, yet complex, tool. Indian Journal of Pathology and Microbiology. 2008 Jan 1;51(1):2-11. https://doi.org/10.4103/0377-4929.40382 PMid:18417841
Sidiropoulos K, Glotsos D, Kostopoulos S, Ravazoula P, Kalatzis I, Cavouras D, Stonham J. Real time decision support system for diagnosis of rare cancers, trained in parallel, on a graphics processing unit. Computers in biology and medicine. 2012 Apr 1;42(4):376-86. https://doi.org/10.1016/j.compbiomed.2011.12.004 PMid:22197115
Prayson RA, Agamanolis DP, Cohen ML, Estes ML, Kleinschmidt-DeMasters BK, Abdul-Karim F, McClure SP, Sebek BA, Vinay R. Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. Journal of the neurological sciences. 2000 Apr 1;175(1):33-9. https://doi.org/10.1016/s0022-510x(00)00274-4 PMid:10785254
Keat N, Law K, McConnell A, Seymour M, Welch J, Trimble T, Lacombe D, Negrouk A. International rare cancers initiative (IRCI). Ecancermedicalscience. 2013 May 21;7:ed20. https://doi.org/10.3332/ecancer.2013.ed20 PMid:24883089 PMCid:PMC4025507
Sharp L, Lewin F, Hellborg H, Lundgren J, Hemmingsson E, Rutqvist LE. When does my treatment start?-The continuum of care for patients with head and neck cancer. Radiotherapy and oncology. 2002 Jun 1;63(3):293-7. https://doi.org/10.1016/S0167-8140(02)00011-7 PMid:12142093
Saloura V, Langerman A, Rudra S, Chin R, Cohen EE. Multidisciplinary care of the patient with head and neck cancer. Surgical Oncology Clinics. 2013 Apr 1;22(2):179-215. https://doi.org/10.1016/j.soc.2012.12.001 PMid:23453331
Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP, MACH-CH Collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiotherapy and oncology. 2011 Jul 1;100(1):33-40. https://doi.org/10.1016/j.radonc.2011.05.036 PMid:21684027
Weinstein GS, O'Malley BW, Cohen MA, Quon H. Transoral robotic surgery for advanced oropharyngeal carcinoma. Archives of Otolaryngology-Head & Neck Surgery. 2010 Nov 15;136(11):1079-85. https://doi.org/10.1001/archoto.2010.191 PMid:21079160
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2004 May 6;350(19):1937-44. https://doi.org/10.1056/NEJMoa032646 PMid:15128893 PMCid:PMC11730226
Lubin JH, Purdue M, Kelsey K, Zhang ZF, Winn D, Wei Q, Talamini R, Szeszenia-Dabrowska N, Sturgis EM, Smith E, Shangina O. Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: a pooled analysis of case-control studies. American journal of epidemiology. 2009 Oct 15;170(8):937-47. https://doi.org/10.1093/aje/kwp222 PMid:19745021 PMCid:PMC2800266
Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil,±docetaxel for larynx preservation. Journal Of The National Cancer Institute. 2016 Apr 1;108(4):djv368. https://doi.org/10.1093/jnci/djv368 PMid:26681800
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. Journal of clinical oncology. 2013 Mar 1;31(7):845-52. https://doi.org/10.1200/JCO.2012.43.6097 PMid:23182993 PMCid:PMC3577950
Veeresh M, Sudhakara M, Girish G, Naik C. Leiomyoma: A rare tumor in the head and neck and oral cavity: Report of 3 cases with review. Journal of Oral and Maxillofacial Pathology. 2013 May 1;17(2):281-7. https://doi.org/10.4103/0973-029X.119770 PMid:24250094 PMCid:PMC3830242
Künzel J, Hainz M, Ziebart T, Pitz S, Ihler F, Strieth S, Matthias C. Head and neck solitary fibrous tumors: a rare and challenging entity. European Archives of Oto-Rhino-Laryngology. 2016 Jun;273(6):1589-98. https://doi.org/10.1007/s00405-015-3670-1 PMid:26026772
Brunet M, Khalifa E, Italiano A. Enabling precision medicine for rare head and neck tumors: the example of BRAF/MEK targeting in patients with metastatic ameloblastoma. Frontiers in oncology. 2019 Nov 12;9:1204. https://doi.org/10.3389/fonc.2019.01204 PMid:31781502 PMCid:PMC6861385
Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome medicine. 2020 Jan 14;12(1):8. https://doi.org/10.1186/s13073-019-0703-1 PMid:31937368 PMCid:PMC6961404
Handorf CR, Kulkarni A, Grenert JP, Weiss LM, Rogers WM, Kim OS, Monzon FA, Halks-Miller M, Anderson GG, Walker MG, Pillai R. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. The American journal of surgical pathology. 2013 Jul 1;37(7):1067-75. https://doi.org/10.1097/PAS.0b013e31828309c4 PMid:23648464 PMCid:PMC5266589
Atienza JA, Dasanu CA. Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature. Current medical research and opinion. 2012 Dec 1;28(12):1899-909. https://doi.org/10.1185/03007995.2012.746218 PMid:23121148
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011 Mar;61(2):69-90. https://doi.org/10.3322/caac.20107 PMid:21296855
Wang HY, Li YY, Shao Q, Hou JH, Wang F, Cai MB, Zeng YX, Shao JY. Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis. Journal of translational medicine. 2012 Feb 9;10(1):27. https://doi.org/10.1186/1479-5876-10-27 PMid:22321704 PMCid:PMC3296637
Alfouzan AF. Head and neck cancer pathology: Old world versus new world disease. Nigerian journal of clinical practice. 2019 Feb 1;22(1). https://doi.org/10.4103/njcp.njcp_310_18 PMid:30666013
da Lilly-Tariah OB, Somefun AO, Adeyemo WL. Current evidence on the burden of head and neck cancers in Nigeria. Head & neck oncology. 2009 May 28;1(1):14. https://doi.org/10.1186/1758-3284-1-14 PMid:19476614 PMCid:PMC2694192
Bhattacharjee A, Chakraborty A, Purkaystha P. Prevalence of head and neck cancers in the north east-an institutional study. Indian Journal of Otolaryngology and head and neck surgery. 2006 Jan;58(1):15-9. https://doi.org/10.1007/BF02907731 PMid:23120228 PMCid:PMC3450618
Seedat J, Coutts K, Vlok E. Epidemiology and demographics of head and neck cancer in Africa: A scoping review. African Journal of Primary Health Care & Family Medicine. 2023;15(1):1-3. https://doi.org/10.4102/phcfm.v15i1.3749 PMid:37526561 PMCid:PMC11022662
Erinoso OA, Okoturo E, Gbotolorun OM, Effiom OA, Awolola NA, Soyemi SS, Oluwakuyide RT. Emerging trends in the epidemiological pattern of head and neck cancers in Lagos, Nigeria. Annals of medical and health sciences research. 2016;6(5):301-7. https://doi.org/10.4103/amhsr.amhsr_30_16 PMid:28503348 PMCid:PMC5414443
Francis D. Trends in incidence of head and neck cancers in India. European Journal of Cancer. 2018 Mar 1;92:S23. https://doi.org/10.1016/j.ejca.2018.01.056
Ahluwalia H, Gupta SC, Singh M, Gupta SC, Mishra V, Singh PA, Walia DK. Spectrum of head-neck cancers at Allahabad. Indian Journal of Otolaryngology and Head & Neck Surgery. 2001 Jan;53(1):16-21. https://doi.org/10.1007/BF02910972 PMid:23119744 PMCid:PMC3450883
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dr. Karthik Shunmugavelu, Dr. Hemalatha Devendran, Shanmugam
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
